The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma.

The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma.

Item
http://www.wikidata.org/entity/Q34532222
Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma.Integrative information theoretic network analysis for genome-wide association study of aspirin exacerbated respiratory disease in Korean population.New and developing non-adrenoreceptor small molecule drugs for the treatment of asthma.Prostaglandins and Their Receptors in Eosinophil Function and As Therapeutic Targets.Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids.Innovative treatments for severe refractory asthma: how to choose the right option for the right patient?Neuroendocrine cells derived chemokine vasoactive intestinal polypeptide (VIP) in allergic diseases.Update in Asthma 2016.Human eosinophils and mast cells: Birds of a feather flock together.Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP2 Receptor Antagonist for Treatment of Asthma.Chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonists in asthma: a systematic review and meta-analysis protocol.New Therapies for Asthma and Chronic Obstructive Pulmonary Disease.Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β2-agonists in patients with atopic asthma.An algorithmic approach for the treatment of severe uncontrolled asthma.Current State and Future of Biologic Therapies in the Treatment of Asthma in ChildrenPotential new targets for drug development in severe asthmaThe prostaglandin D receptor 2 pathway in asthma: a key player in airway inflammation
P2860

The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma.

Item
http://www.wikidata.org/entity/Q34532222
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
The oral CRTh2 antagonist QAW0 ...... uncontrolled allergic asthma.
@ast
The oral CRTh2 antagonist QAW0 ...... uncontrolled allergic asthma.
@en
The oral CRTh2 antagonist QAW039
@nl
type
label
The oral CRTh2 antagonist QAW0 ...... uncontrolled allergic asthma.
@ast
The oral CRTh2 antagonist QAW0 ...... uncontrolled allergic asthma.
@en
The oral CRTh2 antagonist QAW039
@nl
prefLabel
The oral CRTh2 antagonist QAW0 ...... uncontrolled allergic asthma.
@ast
The oral CRTh2 antagonist QAW0 ...... uncontrolled allergic asthma.
@en
The oral CRTh2 antagonist QAW039
@nl
P1433
P1476
P2093
P304
P31
P356
P478
P50
P577
P698
P921
P356
P1433
P1476
The oral CRTh2 antagonist QAW0 ...... uncontrolled allergic asthma.
@en
P2093
P304
P31
P356
10.1016/J.PUPT.2016.06.005
P478
P50
P577
P698
P921